**Table A:** Vaccine-hesitant rheumatic disease patients’ (other than vasculitis patients) concerns around COVID-19 and COVID-19 vaccination in patients who participated in the COVID-19 Vaccine Perceptions Survey.

|  |  |  |
| --- | --- | --- |
|  | **Number of patients who responded:****Number /total responders****(% total responders)** |  |
| **Yes** | **No** | **Not Sure** | **P - Value** |
| **COVID-19 infection concerns** |
| Rheumatic condition increases risk |
| *Vaccine-hesitant patients* | 2/7 (28.5) | 3/7 (42.8) | 2/7 (28.5) | 0.59 |
| *Other rheumatic disease patients* | 53/112 (47.3) | 39/112 (34.8) | 20/112 (17.8) |
| Rheumatic medications increase risk |
| *Vaccine-hesitant patients* | 0/6 (0.0) | 4/6 (66.6) | 2/6 (33.3) | 0.15 |
| *Other rheumatic disease patients* | 43/114 (37.7) | 52/114 (45.6) | 19/114 (16.6) |
| Worse outcomes due to rheumatic condition |
| *Vaccine-hesitant patients* | 2/7 (28.5) | 3/7 (42.8) | 2/7 (28.5) | 0.47 |
| *Other rheumatic disease patients* | 58/112 (51.7) | 35/112 (31.2) | 19/114 (16.6) |
| Consider self at high risk for getting COVID-19 |
| *Vaccine-hesitant patients* | 1/7 (14.2) | 6/7 (85.7) | 0/7 (0.0) | 0.20 |
| *Other rheumatic disease patients* | 51/119 (42.8) | 61/119 (51.2) | 7/119 (5.8) |
| **COVID-19 vaccine concerns** |
| Speed of development |
| *Vaccine-hesitant patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) | **0.01** |
| *Other rheumatic disease patients* | 35/108 (32.4) | 65/108 (60.1) | 8/108 (7.4) |
| Safety |
| *Vaccine-hesitant patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) | **0.04** |
| *Other rheumatic disease patients* | 41/109 (37.6) | 59/109 (54.1) | 9/109 (8.2) |
| Effectiveness |
| *Vaccine-hesitant patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) | 0.08 |
| *Other rheumatic disease patients* | 46/108 (42.5) | 57/108 (52.7) | 5/108 (4.6) |
| Components |
| *Vaccine-hesitant patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) | **0.000** |
| *Other rheumatic disease patients* | 20/105 (19.0) | 70/105 (66.6) | 15/105 (14.2) |
| Severe adverse reactions |
| *Vaccine-hesitant patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) | **0.01** |
| *Other rheumatic disease patients* | 35/108 (32.4) | 68/108 (62.9) | 5/108 (4.6) |
| Side effects |
| *Vaccine-hesitant patients* | 5/7 (71.4) | 2/7 (28.5) | 0/7 (0.0) | 0.18 |
| *Other rheumatic disease patients* | 39/106 (36.7) | 63/106 (59.4) | 4/106 (3.7) |
| Impact on rheumatic condition |
| *Vaccine-hesitant patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) | 0.07 |
| *Other rheumatic disease patients* | 46/110 (41.8) | 57/110 (51.8) | 7/110 (6.3) |
| Impact on rheumatic medications |
| *Vaccine-hesitant patients* | 3/6 (50.0) | 3/6 (50.0) | 0/6 (0.0) | 0.27 |
| *Other rheumatic disease patients* | 24/106 (22.6) | 72/106 (67.9) | 10/106 (9.4) |
| Risk of blood clots |
| *Vaccine-hesitant patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) | 0.07 |
| *Other rheumatic disease patients* | 42/105 (40.0) | 56/105 (53.3) | 7/105 (6.6) |
| Getting COVID-19 from vaccine |
| *Vaccine-hesitant patients* | 4/7 (57.1) | 2/7 (28.5) | 1/7 (14.2) | **0.000** |
| *Other rheumatic disease patients* | 5/101 (4.9) | 89/101 (88.1) | 7/101 (6.9) |
| Know what to do with medications if they get a COVID-19 vaccine |
| *Vaccine-hesitant patients* | 0/6 (0.0) | 4/6 (66.6) | 2/6 (33.3) | 0.17 |
| *Other rheumatic disease patients* | 41/109 (37.6) | 45/109 (41.2) | 23/105 (21.9) |

**Table B:** Vaccine-hesitant vasculitis and other vaccine-hesitant rheumatic disease patients’ concerns around COVID-19 and COVID-19 vaccination in patients who participated in the COVID-19 Vaccine Perceptions Survey.

|  |  |  |
| --- | --- | --- |
|  | **Number of patients who responded:****Number /total responders** **(% total responders)** |  |
| **Yes** | **No** | **Not Sure** | **P – value**  |
| **COVID-19 infection concerns** |
| Rheumatic condition increases risk |
| *Vaccine-hesitant vasculitis patients* | 6/10 (60.0) | 4/10 (40.0) | 0/10 (0.0) | 0.15 |
| *Vaccine-hesitant rheumatic disease patients* | 2/7 (28.5) | 2/7 (28.5) | 3/7 (42.8) |
| Rheumatic medications increase risk |
| *Vaccine-hesitant vasculitis patients* | 3/9 (33.3) | 5/9 (55.5) | 1/9 (11.1) | 0.22 |
| *Vaccine-hesitant rheumatic disease patients* | 0/6 (0.0) | 4/6 (66.6) | 2/6 (33.3) |
| Worse outcomes due to rheumatic condition |
| *Vaccine-hesitant vasculitis patients* | 5/10 (50.0) | 3/10 (30.0) | 2/10 (20.0) | 0.67 |
| *Vaccine-hesitant rheumatic disease patients* | 2/7 (28.5) | 3/7 (42.8) | 2/7 (28.5) |
| Consider self at high risk for getting COVID-19 |
| *Vaccine-hesitant vasculitis patients* | 5/10 (50.0) | 3/10 (30.0) | 2/10 (20.0) | 0.07 |
| *Vaccine-hesitant rheumatic disease patients* | 1/7 (14.2) | 6/7 (85.7) | 0/7 (0.0) |
| **COVID-19 vaccine concerns** |
| Speed of development |
| *Vaccine-hesitant vasculitis patients* | 8/10 (80.0) | 2/10 (20.0) | 0/10 (0/0) | 0.76 |
| *Vaccine-hesitant rheumatic disease patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) |
| Safety |
| *Vaccine-hesitant vasculitis patients* | 10/10 (100.0) | 0/10 (0.0) | 0/10 (0.0) | 0.21 |
| *Vaccine-hesitant rheumatic disease patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) |
| Effectiveness |
| *Vaccine-hesitant vasculitis patients* | 7/10 (70.0) | 1/10 (10.0) | 2/10 (20.0) | 0.45 |
| *Vaccine-hesitant rheumatic disease patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) |
| Components |
| *Vaccine-hesitant vasculitis patients* | 8/10 (80.0) | 0/10 (0.0) | 2/10 (20.0) | 0.24 |
| *Vaccine-hesitant rheumatic disease patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) |
| Severe adverse reactions |
| *Vaccine-hesitant vasculitis patients* | 9/10 (90.0) | 1/10 (10.0) | 0/10 (0.0) | 0.78 |
| *Vaccine-hesitant rheumatic disease patients* | 6/7 (85.7) | 1/7 (10.0) | 0/10 (0.0) |
| Side effects |
| *Vaccine-hesitant vasculitis patients* | 7/10 (70.0) | 3/10 (30.0) | 0/10 (0.0) | 0.94 |
| *Vaccine-hesitant rheumatic disease patients* | 5/7 (71.4) | 2/7 (28.5) | 0/7 (0.0) |
| Impact on rheumatic condition |
| *Vaccine-hesitant vasculitis patients* | 9/10 (90.0) | 1/10 (10.0) | 0/10 (0.0) | 0.78 |
| *Vaccine-hesitant rheumatic disease patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) |
| Impact on rheumatic medications |
| *Vaccine-hesitant vasculitis patients* | 5/10 (50.0) | 3/10 (30.0) | 2/10 (20.0) | 0.44 |
| *Vaccine-hesitant rheumatic disease patients* | 3/6 (50.0) | 3/6 (50.0) | 0/6 (0.0) |
| Risk of blood clots |
| *Vaccine-hesitant vasculitis patients* | 7/10 (70.0) | 2/10 (20.0) | 1/10 (10.0) | 0.63 |
| *Vaccine-hesitant rheumatic disease patients* | 6/7 (85.7) | 1/7 (14.2) | 0/7 (0.0) |
| Getting COVID-19 from vaccine |
| *Vaccine-hesitant vasculitis patients* | 5/10 (50.0) | 4/10 (40.0) | 1/10 (10.0) | 0.88 |
| *Vaccine-hesitant rheumatic disease patients* | 4/7 (57.1) | 2/7 (28.5) | 1/7 (14.2) |
| Know what to do with medications if they get a COVID-19 vaccine |
| *Vaccine-hesitant vasculitis patients* | 1/10 (10.0) | 6/10 (60.0) | 3/10 (30.0) | 0.72 |
| *Vaccine-hesitant rheumatic disease patients* | 0/6 (0.0) | 4/6 (66.6) | 2/6 (33.3) |